Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte
Baojuan Han, Lina Dong, Jing Zhou, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 10, pp. 2893-2909
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 92
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Circulating proteins as predictive and prognostic biomarkers in breast cancer
Hugo Veyssière, Yannick Bidet, Frédérique Penault‐Llorca, et al.
Clinical Proteomics (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 41
Characteristics of Soluble PD‐L1 and PD‐1 Expression and Their Correlations With Immune Status and Prognosis in Advanced Lung Cancer
Ran Li, Hongge Liang, Ying Shang, et al.
Asia-Pacific Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
Fabio Scirocchi, Lidia Strigari, Alessandra Di Filippo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14496-14496
Open Access | Times Cited: 32
Progresses in biomarkers for cancer immunotherapy
Xuwen Lin, Chenyu Zong, Zhihan Zhang, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 20
Enzyme-catalyzed electrochemical aptasensor for ultrasensitive detection of soluble PD-L1 in breast cancer based on decorated covalent organic frameworks and carbon nanotubes
Yue Zhang, Shuyi Chen, Jie Ma, et al.
Analytica Chimica Acta (2023) Vol. 1282, pp. 341927-341927
Closed Access | Times Cited: 15
Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives
Mohammad Sadegh Soltani‐Zangbar, Forough Parhizkar, Mojtaba Abdollahi, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 21
Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
Christina Bruß, Kerstin Kellner, Veruschka Albert, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2615-2615
Open Access | Times Cited: 11
Prognostic significance of soluble PD-L1 in prostate cancer
Margarita Zvirble, Žilvinas Survila, Paulius Bosas, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
Nikolay E. Kushlinskii, О. В. Ковалева, Alexei Gratchev, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 500-500
Open Access
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Myriam Kossaï, Nina Radosevic‐Robin, Frédérique Penault‐Llorca
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100257-100257
Open Access | Times Cited: 25
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
Nonkululeko Z. Malinga, Shalete C. Siwele, Helen C. Steel, et al.
Translational Oncology (2022) Vol. 19, pp. 101384-101384
Open Access | Times Cited: 16
Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Guixiang Liao, Zhihong Zhao, Yuting Qian, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21
Therapeutic implications for the PD-1 axis in cerebrovascular injury
James Feghali, Christopher M. Jackson
Neurotherapeutics (2024), pp. e00459-e00459
Open Access | Times Cited: 2
Inflammasomes in breast cancer: the ignition spark of progression and resistance?
Sawsan Elgohary, H.M. El Tayebi
Expert Reviews in Molecular Medicine (2023) Vol. 25
Closed Access | Times Cited: 6
Magnetoresistance and magneto-plasmonic sensors for the detection of cancer biomarkers: A bibliometric analysis and recent advances
Fahad Usman, Kamarul Hawari Ghazali, Razali Muda, et al.
Sensors and Actuators Reports (2023) Vol. 6, pp. 100172-100172
Open Access | Times Cited: 6
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
Ioannis Vathiotis, Georgia Gomatou, Dimitrios J. Stravopodis, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5383-5383
Open Access | Times Cited: 14
Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
Seri Jeong, Nuri Lee, Min-Jeong Park, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5225-5225
Open Access | Times Cited: 14
Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
Ling Yi, Xiaojue Wang, Siyun Fu, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage
Qin Li, Cuishan Chen, Jiaming Wu, et al.
Human Reproduction (2023) Vol. 38, Iss. 11, pp. 2128-2136
Closed Access | Times Cited: 4
Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
Sawsan Elgohary, Reda A. Eissa, H.M. El Tayebi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14254-14254
Open Access | Times Cited: 4
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma
Mahlatse Kgokolo, Nonkululeko Z. Malinga, Helen C. Steel, et al.
Translational Oncology (2024) Vol. 42, pp. 101867-101867
Open Access | Times Cited: 1
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy
Sinne Søberg Brun, Torben Frøstrup Hansen, Sara Witting Christensen Wen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer
Ali Ameri, Bahareh Tavakoli‐Far, Maryam Rostami, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109334-109334
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top